Summary & Overview
HCPCS G9558: Beta-lactam Antibiotic as Definitive Therapy
HCPCS Level II code G9558 indicates that a patient was treated with a beta-lactam antibiotic as definitive therapy after pathogen identification and susceptibility testing. This code captures a clinical decision point in antimicrobial management and is relevant to documentation, antimicrobial stewardship, and quality reporting tied to infection care. Nationally, use of a dedicated HCPCS Level II code for definitive beta-lactam therapy supports consistent recording across care settings and can inform utilization and stewardship efforts.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code's clinical context, where the service is commonly delivered, and what coverage stakeholders typically consider when reviewing claims for definitive antimicrobial therapy. The publication provides benchmarks and policy context where available, highlights coding considerations for documentation of definitive therapy, and outlines implications for quality measurement and reporting.
This analysis is written for a national audience and does not include state-specific guidance. Data not available in the input will be identified where necessary; the primary focus is on clinical meaning, common sites of service, payer coverage scope, and the operational implications of using HCPCS Level II code G9558 in claims and quality workflows.
Billing Code Overview
HCPCS Level II code G9558 denotes patient treated with a beta-lactam antibiotic as definitive therapy. The service represents documentation that a patient received a beta-lactam antibiotic (such as a penicillin, cephalosporin, or carbapenem class agent) as the definitive antimicrobial therapy following identification of the pathogen and susceptibility results.
Service Type: Antimicrobial therapy administration and documentation provided as part of infection management and antimicrobial stewardship.
Typical Site of Service: Inpatient hospital or outpatient infusion/clinic setting, where definitive antimicrobial therapy is selected and administered following microbiology results. If additional site details are required, Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient admitted to the hospital for community-acquired pneumonia initially received empiric broad-spectrum antibiotics. After microbiology results from blood and sputum cultures identify a susceptible Streptococcus pneumoniae and susceptibility testing confirms sensitivity to a penicillin-class agent, the infectious diseases clinician and the primary team de-escalate therapy to a beta-lactam antibiotic as definitive therapy (G9558). Treatment is administered either orally or intravenously depending on the patient's clinical status. Typical workflow includes review of culture and sensitivity reports, documentation of definitive therapy selection in the medical record, adjustment of antibiotic orders by the prescribing clinician, and nursing administration and monitoring for efficacy and adverse reactions. The typical site of service is the inpatient acute care setting, including medical wards and the intensive care unit; outpatient infusion centers or observation units may also administer definitive beta-lactam therapy when culture results permit transition from empiric agents.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or complexity of managing definitive antibiotic therapy is substantially greater than typical (e.g., complex dosing adjustments for severe renal impairment). |